[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632435":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":23,"studyPopulation":16,"armGroups":24,"interventions":36,"overallOfficials":16,"centralContacts":16,"locations":16,"responsibleParty":46,"collaborators":16,"id":48,"slug":16,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":23,"acronym":16,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":16,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":16,"overallStatus":66,"whyStopped":16,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":16},{"fullName":5,"class":6},"Dong-A ST Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":16},[9,13],{"measure":10,"description":11,"timeFrame":12},"AUCt","Area under the plasma concentration-time curve during dosing interval (AUCt)","pre-dose (0hour) to 72hours",{"measure":14,"description":15,"timeFrame":12},"Cmax","Maximum concentration of drug in plasma",null,{"allocation":18,"interventionModel":19,"interventionModelDescription":16,"primaryPurpose":20,"observationalModel":16,"timePerspective":16,"maskingInfo":21},"RANDOMIZED","CROSSOVER","TREATMENT",{"masking":22,"maskingDescription":16,"whoMasked":16},"NONE","An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of DA-5230 With DA-5230-R in Healthy Adult Volunteers",[25,32],{"label":26,"type":27,"description":28,"interventionNames":29},"Sequence A","EXPERIMENTAL","Period 1(DA-5230-R), Period 2(DA-5230)",[30,31],"Drug: DA-5230","Drug: DA-5230-R",{"label":33,"type":27,"description":34,"interventionNames":35},"Sequence B","Period 1(DA-5230), Period 2(DA-5230-R)",[30,31],[37,42],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":16},"DRUG","DA-5230","Test drug",[26,33],{"type":38,"name":43,"description":44,"armGroupLabels":45,"otherNames":16},"DA-5230-R","Reference drug",[26,33],{"type":47,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR","100632435",false,"NCT07513649","A Study to Evaluate the Bioequivalence of DA-5230 Compared to DA-5230-R","Inclusion Criteria:\n\n* Healthy participants aged 19 to 55 years at the time of screening visit\n* Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n\nExclusion Criteria:\n\n* Participants who have received an investigational product in another clinical trial or a bioequivalence study within 6 months prior to the first dosing\n* Participants deemed unsuitable for participation in this clinical trial by the investigator",true,"ALL","19 Years","55 Years",{"count":58,"type":59},60,"ESTIMATED","INTERVENTIONAL",[62],"PHASE1","A study to evaluate the bioequivalence of DA-5230 compared to DA-5230-R",[65],"Healthy Adult Participants","NOT_YET_RECRUITING","2026-03-31",{"date":69,"type":70},"2026-04-07","ACTUAL",{"date":72,"type":59},"2026-04",{"date":74,"type":59},"2026-05",{"name":5,"class":6}]